Clinical trial
Arsenic Trioxide in Treating Patients With Acute Myeloid Leukemia
NCT00005795 · Northwestern University, Other · Completed
Key facts
| NCT number | NCT00005795 |
|---|---|
| Title | Arsenic Trioxide in Treating Patients With Acute Myeloid Leukemia |
| Official title | Phase II Trial of Arsenic Trioxide in Relapsed and Refractory Acute Myeloid Leukemia, Secondary Leukemia, and/or Newly-Diagnosed Patients Greater Than or Equal to 65 Years Old |
| Lead sponsor | Northwestern University, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Leukemia |
| Intervention type | Drug |
| Interventions | arsenic trioxide |
| Enrollment | 11 |
| Start date | Feb 1, 2000 |
| Primary completion | Jul 1, 2002 |
| Completion | Jul 1, 2002 |
| First posted | Feb 16, 2004 |
| Last update posted | Jun 11, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: